<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TRASTUZUMAB</span><br/>(tra-stu'zu-mab)<br/><span class="topboxtradename">Herceptin<br/></span><b>Classifications:</b> <span class="classification"> immunosuppressant</span>; <span class="classification">monoclonal antibody</span>; <span class="classification">anti-her</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>440 mg vial</p>
<h1><a name="action">Actions</a></h1>
<p>Recombinant DNA monoclonal antibody (I<sub>g</sub>G<sub>1</sub> kappa) that selectively binds to the human epidermal growth factor receptor-2 protein (HER<sub>2</sub>).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits growth of human tumor cells that over express HER<sub>2</sub> proteins.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Metastatic breast cancer in those whose tumors over express the HER<sub>2</sub> protein.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Concurrent administration of anthracycline or radiation; lactation during and for 6 mo following administration of trastuzumab.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Preexisting cardiac dysfunction; previous administration of cardiotoxic therapy (e.g., anthracycline or radiation); pregnancy
         (category B); older adults; hypersensitivity to benzyl alcohol (preservative in bacteriostatic water).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Metastatic Breast Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV Loading Dose</span> 4 mg/kg <span class="rdroute">IV Maintenance Dose</span> 2 mg/kg qwk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Reconstitute each vial with 20 mL of supplied diluent (bacteriostatic water) to produce a multidose vial containing 21 mg/mL.
                  Note: For patients with a hypersensitivity to benzyl alcohol, reconstitute with sterile water for injection; this solution
                  must be used immediately with any unused portion discarded. Withdraw the ordered dose and add to a 250-mL of NS and invert
                  bag to mix. Do not give or mix with dextrose solutions.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Infuse loading dose (4 mg/kg) over 90 min; infuse subsequent doses (2 mg/kg) over 30 min. Do not give IV push or as a bolus
                  dose.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> Dextrose solution; do not mix or coadminister with other drugs. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store unopened vials and reconstituted vials at 2°8° C (36°46° F). Discard reconstituted vials
            28 days after reconstitution.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> <span class="speceff-common">Pain, asthenia, fever, chills,</span> flu syndrome, allergic reaction, bone pain, arthralgia, <span class="speceff-life">hypersensitivity (anaphylaxis, urticaria, bronchospasm, angioedema, or hypotension)</span>, increased incidence of infections, infusion reaction (<span class="speceff-common">chills, fever,</span> nausea, vomiting, pain, rigors, headache, dizziness, dyspnea, hypotension, rash). <span class="typehead">CNS:</span> <span class="speceff-common">Headache, insomnia, dizziness, paresthesias,</span> depression, peripheral neuritis, neuropathy. <span class="typehead">CV:</span> <span class="speceff-life">CHF</span>, cardiac dysfunction (dyspnea, cough, paroxysmal nocturnal dyspnea, peripheral edema, S3 gallop, reduced ejection fraction),
      tachycardia, edema, cardiotoxicity. <span class="typehead">GI:</span> <span class="speceff-common">Diarrhea, abdominal pain, nausea, vomiting,</span> anorexia. <span class="typehead">Hematologic:</span> <span class="speceff-common">Anemia, leukopenia.</span> <span class="typehead">Respiratory:</span> <span class="speceff-common">Cough, dyspnea,</span> rhinitis, pharyngitis, sinusitis. <span class="typehead">Skin:</span> <span class="speceff-common">Rash,</span> herpes simplex, acne. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Paclitaxel</b> may increase trastuzumab levels and toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Half-Life:</span> 5.8 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Periodically monitor CBC with differential, platelet count, and Hgb and Hct.</li>
<li>Monitor for chills and fever during the first IV infusion; these adverse events usually respond to prompt treatment without
            the need to discontinue the infusion. Notify physician immediately.
         </li>
<li>Monitor carefully cardiovascular status at baseline and throughout course of therapy, assessing for S&amp;S of heart failure (e.g.,
            dyspnea, increased cough, PND, edema, S3 gallop). Those with preexisting cardiac dysfunction are at high risk for cardiotoxicity.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly any unusual symptoms (e.g., chills, nausea, fever) during infusion.</li>
<li>Report promptly any of the following: Shortness of breath, swelling of feet or legs, persistent cough, difficulty sleeping,
            loss of appetite, abdominal bloating.
         </li>
<li>Do not breast feed during and for 6 mo following administration of trastuzumab.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>